cyrilzakka/clinical-trials huggingface dataset:
Correlation Between RMI of Degenerative Disk Disease and Reduction of Pain After Disk-infiltration Treatments

The primary objective of the study is to demonstrate the difference in the reduction of pain at 1 month after intradiscal infiltration of corticosteroids depending on symmetrical or asymmetrical active discopathies with MRI examination. The difference should be judged significant if it ⩾ 2 points.

As secondary objective, the study aims to study the correlation between pain reduction which will be assessed by numerical scale at 1 month and 6 months after intradiscal infiltration of corticosteroids and following parameters: the duration of chronic lumbago, the presence of associated root pains, the morphological characteristics with RMI examination of active discopathies, the co-existence of scoliosis, the sign of inter-somatic instability, the muscular trophicity of muscle erector of low back, the pelvic incidence, degree of lumbar lordosis, Cobb angle, wearing a corset.

Eligibility Criteria:
Inclusion Criteria:

* Age ⩾ 18 years.
* Chronic growing lumbago with duration \> 3 mois.
* Disabling lumbago with an average ⩾ 4/10 defined by numerical scale.
* Common chronic low back pain that has been evolving for more than 3 months.
* Disabling lumbalgia defined by an average numerical scale greater than or equal to 4/10 in the month preceding the inclusion.
* Failure or intolerance to drug treatments (nonsteroidal anti-inflammatory drugs and systemic corticosteroids).
* Absence of biological inflammatory syndrome.
* Recent MRI of less than 6 months with active disc disease (Modic 1) defined by degenerative disc disease associated with mirror rearrangements of the subchondral bone of the adjacent vertebral endplates in hyposignal T1 and hypersignal T2.
* Signed informed consent obtained.
* Affiliation to social security.

Exclusion Criteria:

* Pregnancy woman.
* Immunosuppression.
* History of allergy to iodinated contrast agents and / or prednisolone acetate.
* Local or general infection.
* Fever (temperature\> 38).
* History of disc surgery of less than 6 months.
* History of infectious spondylodiscitis.
* Unbalanced psychiatric disorders.
* Severe coagulation disorders or impossible cessation of anticoagulation or anti platelet aggregation.
* Impossibility to obtain signed consent form.
* Patient under guardianship and/or curatorship.
Pharmacodynamics of Omiganan BID in Patients With Atopic Dermatitis

This study has a randomized, double-blind, placebo-controlled design to assess the efficacy, pharmacodynamics and safety/tolerability of omiganan in patients with mild to moderate atopic dermatitis when applied BID to all atopic dermatitis lesions.


Eligibility Criteria:
Inclusion Criteria:

* Male and female subjects with mild to moderate AD (IGA 2 or 3) 18 to 65 years of age,inclusive. The health status is verified by absence of evidence of any clinical significant active or uncontrolled chronic disease other than AD following a detailed medical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, virology and urinalysis;
* Confirmed AD diagnosis;
* Symptoms present for at least 1 year;
* EASI between 7.1 - 50.0, inclusive at screening;
* 2-20% body surface area (BSA) affected at screening;
* Body mass index (BMI) between 18 and 35 kg/m2, inclusive, and with a minimum weight of 50 kg;
* Able to participate and willing to give written informed consent and to comply with the study restrictions;
* Subjects and their partners of childbearing potential must use effective contraception, for the duration of the study and for 3 months after the last dose.

Exclusion Criteria:

* Any current and / or recurrent clinical significant skin condition other than AD;
* Pregnant, a positive pregnancy test, intending to become pregnant, or breastfeeding;
* Ongoing use of prohibited atopic dermatitis treatments. Requires washout period prior to baseline (first dose of the study drug);
* Use of topical medication (prescription or over-the-counter \[OTC\]) within 14 days of study drug administration, or less than 5 half-lives (whichever is longer) in local treatment area;
* Tanning due to sunbathing, excessive sun exposure or a tanning booth within 3 weeks of enrollment;
* Known hypersensitivity to the compound or excipients of the compound or known hypersensitivity to one or more different emollients;
* Participation in an investigational drug or device study within 3 months prior to screening or more than 4 times a year;
* Loss or donation of blood over 500 mL within three months (males) or four months (females) prior to screening.
Diagnostic Accuracy of Bedside Ultrasound in Suspected Acute Diverticulitis

Colonic diverticulitis is a common clinical condition in patients presenting to the Emergency Department (ED) with abdominal pain. The diagnosis and staging of patients with suspected acute diverticulitis is often made by CT imaging with intravenous contrast, which involves radiation exposure, is expensive and has contraindications. The aim of this study is to evaluate the diagnostic accuracy and role of bedside abdominal US for the diagnosis of acute diverticulitis

Colonic diverticulitis is a common clinical condition; about 20% of patients with colonic diverticulosis experience abdominal symptoms and, eventually, complications such as episodes of diverticulitis or bleeding. The distinction between patients with uncomplicated or complicated diverticulitis affects the clinical management: medical therapy for the first, interventional therapy for the latter. CT imaging with intravenous contrast has become the gold standard in the diagnosis and staging of patients with suspected acute diverticulitis but, unfortunately, CT involves radiation exposure, is expensive and has contraindications. UltraSound (US) is a real-time dynamic examination with wide availability and easy accessibility and may be useful in diagnosing and managing critically ill patients who cannot be moved to CT. In a recent meta-analysis, US exam performed by Radiologists showed a pooled sensitivity of 90% (vs 95% for CT, p = 0.86) and a specificity of 90% (vs 96% for CT, p = 0.04). US is increasingly used at bedside to rapidly assess patients presenting to the Emergency Department. No previous studies have investigated the diagnostic accuracy of abdominal US performed by physician at bedside as an extension of physical examination. This study evaluates the diagnostic accuracy of bedside abdominal US.

Eligibility Criteria:
Inclusion Criteria:

* informed consent obtained
* patients with abdominal pain presenting to the Emergency Department with a suspicon of diverticular disease, in whom the tutor physician orders an imaging study (abdominal CT or abdominal US performed by the Radiologist)

Exclusion Criteria:

* no ultrasonographer physician who can perform bedside abdominal US is present
* the patient does not undergo imaging study
* clinical conditions of the patient are particularly severe, preventing an adequate enrollment
Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas

This is a perspective multicentric study for the treatment of patients aged equal or less than 60 years and submitted to an allogeneic hematopoietic stem cell transplantation from an HLA compatible related or unrelated donor because affected by resistent or refractory or relapsed after autologous stem cell transplantation Ewing Sarcoma or Soft tissues sarcoma who did not benefit from conventional therapy.


Eligibility Criteria:
Inclusion Criteria:

* Age 0-60 years.
* Performance status according to Karnofsky score \> 70%
* Normal liver function
* Normal renal function
* Normal cardiac function
* Informed consent
* Availability of an HLA compatible Donor

Exclusion Criteria:

* Absence of at least one of the inclusion criteria
Effects of Atx and Oros-mph on Executive Functions

The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).

The aim of this study was to evaluate and compare the effects of Atomoxetine(ATX) and osmotic release oral system-methylphenidate (OROS-MPH) therapies on executive functions, activities, treatment response time and adverse effects based on discernible clinical effects in children with combined type attention deficit-hyperactivity disorder (ADHD).

In this study, the functional capabilities of the patients who clinically responded well to therapy were assessed simultaneously with clinical response that may appear at different time periods and the treatment groups were compared in patients who responded to therapy by excluding patients with insufficient clinical response.

Eligibility Criteria:
Inclusion Criteria:

* Combined type ADHD diagnosis was made by a child psychiatrist according to DSM-IV criteria through K-SADS interview with the patient and mother
* The Clinical Global Impression Scale (CGI-S) was applied to determine ADHD severity and patients with a CGI-S score≥4

Exclusion Criteria:

* Psychological, neurological or psychiatric diseases other than ADHD,
* ADHD types other than combined type,
* Medication that influences cognitive processes or history of such medication,
* WISC-R scores \<80 or \>120
Diagnostic Modalities for Severe Odontogenic Infections Using Rapid, Target Enriched Multiplex PCR (TEM- PCR) by Diatherix

The purpose of the study is to evaluate the sensitivity and specificity of the Target Enriched Multiplex (TEM) polymerase chain reaction (PCR) platform for the rapid molecular diagnosis and treatment of odontogenic deep space neck infections.


Eligibility Criteria:
Inclusion Criteria:

* Patients in whom there is clinical and radiographic evidence of an odontogenic deep space neck infection.

Exclusion Criteria:

* Patients with gross communication between the abscess and the oral cavity will be excluded.
Hyaluronic Acid Gel in Prevention of Intrauterine Adhesions After Endometrial Ablation

The aim of the study is to evaluate if hyaluronic acid gel prevents intrauterine adhesion formation after endometrial thermal ablation.


Eligibility Criteria:
Inclusion Criteria:

* menorrhagia

Exclusion Criteria:

* abnormal uterine cavity,
* abnormal endometrial biopsy
Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer patients.

Analysis will be performed on the most recent Transurethral resection of bladder tumor (TURBT) histologic specimen obtained prior to BCG induction and on histologic specimens at time of recurrence after BCG induction. This stratification is of potential utility to clinicians for patient counseling purposes, for the identification of patients likely to benefit from induction or re-induction with BCG, and for consideration of alternative treatment strategies including clinical trials, chemotherapy, or cystectomy. Additionally, there is currently no reliable tool for identifying which NMIBC patients are most likely to benefit from adjuvant BCG versus intravesical chemotherapy. This is of current relevance in the management of Intermediate-risk (IR) NMIBC since both BCG and chemotherapy are first-line treatment options and will likely become of increasing relevance in High-risk (HR) NMIBC as efficacious first-line alternatives to intravesical BCG are introduced into clinical practice. In the proposed prospective study, the study team also aims to develop and then validate an AI-based histologic analysis tool for clinicians that is intended to predict recurrence following intravesical chemotherapy in IR and HR NMIBC patients.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of intermediate or high-risk non-muscle invasive bladder cancer as defined by AUA/SUO criteria (Intermediate-risk: recurrence within 1 year low grade Ta, solitary low grade Ta \>3 cm, multifocal low grade Ta, high grade Ta ≤3 cm, low grade T1; High risk: high grade T1, recurrent high grade Ta, high grade Ta \>3 cm, multifocal high grade Ta, any CIS, any BCG failure in high grade disease, any variant histology, any lymphovascular invasion) following pathologic evaluation of tissue specimens from TURBT.
* Intravesical therapy within 6 months from enrollment including patients treated with BCG, mitomycin C, or Gemcitabine/Docetaxel.
* English or Spanish speakers
* ≥ 18 years of age
* Ability to understand and the willingness to provide an informed consent

Exclusion Criteria:

* Inadequate tissue from TURBT
* ≥ T2 bladder cancer
* Systemic therapy
* Inability to read or write English or Spanish
* Unwilling to sign written informed consent
Effects of Electrical Stimulation on Osteoarthritis of the Knee

The purpose of this study is to find out whether electrical stimulation can reduce knee pain and increase function in people with osteoarthritis of the knee.


Eligibility Criteria:
Inclusion Criteria:

* 50 years of age or older
* Diagnosis of primary osteoarthritis of the knee (as defined by American College of Rheumatology criteria)
* Knee pain of at least six months duration
* Moderate or greater knee pain (defined as a score of 3 or greater on an 11 point numeric pain rating scale) for most days in the last month
* Willing to abide by protocol and treatment schedule.

Exclusion Criteria:

* Implants, such as pacemaker, TENS, or insulin pump, incompatible with electrical stimulation
* Uncontrolled concomitant disease affecting the knee, such as: rheumatoid arthritis, systemic lupus erythema, psoriatic arthritis
* Pregnant or breast-feeding
* Intra-articular corticosteroid or hyaluronic acid injection into the knee within 3 months preceding study
* Arthroscopy of the knee within the past year
* Significant injury to the knee within the past 6 months
* Use of assistive devices other than a cane or knee brace
* Disease of spine or other lower extremity joints of sufficient degree to affect assessment of the knee
Phase I Study of Olaparib With Cisplatin Based Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

The aim of this study is to find the safe dose and best dosing schedule of olaparib to give in combination with cisplatin based chemoradiotherapy (CRT) in patients with locally advanced head and neck cancer. The dose decided on in this part of the study will become the recommended dose for the randomised Phase II trial.

This is a dose escalating Phase I/II trial evaluating the safety and tolerability of the addition of olaparib to CRT in high risk locally advanced human papillomavirus (HPV) negative Squamous Cell Carcinoma of the Head and Neck (HNSCC). A fixed dose of weekly cisplatin and intensity-modulated radiation therapy (IMRT) will be used, with doses of olaparib escalating for consecutive days and both dose level and duration will be increased through each cohort.

This Phase I trial will assess how olaparib, a poly ADP ribose polymerase (PARP) inhibitor is tolerated when added to standard chemoradiotherapy treatment.

Patients will be recruited from sites in the UK only.

A placebo controlled, randomised Phase II trial will follow once the recommended dose and schedule of olaparib has been established.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed high risk, locally advanced HNSCC patients (TNM staging: T-any N2/3 M0, bulky T3 or T4 N-any M0) who would normally be offered cisplatin-based radical chemoradiotherapy
* Estimated life expectancy of at least 12 weeks
* WHO performance status of 0 or 1
* Aged ≥18 years of age
* Adequate major organ function
* Willing to use contraception for the duration of the trial treatment and for six months after completion of treatment
* Able to give informed consent
* Willing and able to comply with the protocol for the duration of the study

Exclusion Criteria:

* Head \& neck cancers of the following types:
* Nasopharyngeal and paranasal sinus tumours,
* Oral squamous cell carcinomas (tumours of the oral cavity),
* Human Papilloma Virus positive oropharyngeal tumours (tonsillar and tongue base tumours)
* Confirmed distant metastatic disease
* Previous chemotherapy or radiotherapy for the treatment of HNSCC tumour
* Previous therapy with a PARP inhibitor
* Pre-existing gastrointestinal disorders that may interfere with the delivery or absorption of olaparib
* Grade 3 or 4 peripheral neuropathy
* Significant hearing difficulties or tinnitus (deaf patients can be included)
* The current use of drugs which are known to inhibit or induce CYP3A4
A Database for Emotion Analysis Using Physiological and Psychological Assessment by 40FY

A comprehensive study examining the physiological, emotional and psychological aspects of stress among Korean adults

A dataset for the analysis of affective states of Korean adults. Participants' facial and finger videos were recorded using a cell phone camera, while watching six emotion-eliciting video stimuli, each three minutes in length (two of each: neutral, positive, and negative). Participants were asked to rate their emotion and arousal in terms of arousal and valence levels. The ECG data were collected using a 1-lead ECG while watching the six emotion-eliciting video stimuli. Psychological assessments were conducted using self-administered scales measuring psychological status and personality.

Eligibility Criteria:
Inclusion Criteria:

* Adults over the age of 19 and under the age of 45.

Exclusion Criteria:

* Participants vulnerable to voluntary consent, such as those who have evidence of intellectual disability or traumatic brain injury
* Participants who have difficulty reading and understanding Korean.
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)

This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group.

This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group. Following informed consent and screening, participants with ALS will take Theracurmin 1 capsule (90mg) twice daily for 6-months. Treatment with the Theracurmin and all study outcome measures and labs are being performed exclusively for research purposes. Collected data includes saliva and stool microbiome sampling, adverse events, concomitant medications, weight and height, Theracurmin treatment evaluations, and Thrive Questionnaires. Participants will be asked to register on the website Patientslikeme.

Eligibility Criteria:
Inclusion Criteria:

* Male or female, aged at least 18 years.
* Sporadic or familial ALS diagnosed as possible, laboratory-supported probable, probable, or definite as defined by revised El Escorial criteria.
* Patient is able to understand and express informed consent (in the opinion of the site investigator).
* Patient has access to the Internet on a desktop computer, laptop, or tablet and has a working email address.
* Patient or caregiver is willing and able to use a computer and enter data on a secure website.
* Patient is able to read and write English.
* Patient is expected to survive for the duration of the trial.
* Women must not be pregnant (will have evidence of a negative pregnancy test obtained by local physician within past 7 days or be post-menopausal)
* Women must not be able to become pregnant (e.g., post-menopausal, surgically sterile, or using adequate birth control methods) for the duration of the study and three months after study completion. Adequate contraception includes: abstinence, hormonal contraception (oral contraception, implanted contraception, injected contraception or other hormonal contraception, for example patch or contraceptive ring), intrauterine device (IUD) in place for ≥ 3 months, barrier method in conjunction with spermicide, or another adequate method.

Exclusion Criteria:

* Patient is taking other experimental treatments for ALS (those that are part of an active research study).
* Prior side effects from curcumin or turmeric containing products
* Patient has a medical or psychiatric illness that could in the investigator's opinion interfere with the patient's ability to participate in this study.
* Pregnant women or women currently breastfeeding.
* Life expectancy shorter than the duration of the trial.
* Taking an antiplatelet agent or anticoagulant (due to the theoretically increased risk of bleeding from curcumin products).
Effectiveness of CC VS Aerobic Exercise for Strengthening and Improving QOL in Post Stroke Patients

To determine the effects of closed chain versus aerobic exercise for strengthening and improving quality of life in post stroke patients


Eligibility Criteria:
Inclusion Criteria:

* Hemiplegic post stroke patients (either left or right side)
* Patients of both gender
* Age range in between 40 to 60
* Patient with cognitive functioning

Exclusion Criteria:

* History of any cardiac problem
* Recurrent stroke
* Any kind of disability or amputated limb
* Neurological conditions like Parkinsonism, epilepsy and
* spinal cord injury.
* Any kind of fracture or dislocation history.
Early Detection of Cardiac Damage by Two-Dimensional Speckle Tracking Echocardiography After Thoracic Radiation Therapy

The purpose of this study is to detecte and predict early subclinical cardiac damage induced by thoracic radiation therapy based on two-dimensional speckle tracking echocardiography combined with multiple circulating biomarkers.

This is a monocentric prospective cohort study in which 100 patients treated for malignant tumors and with cardiac radiation exposure will be included.All patient will be followed for 12 months after radiotherapy. Echocardiography, 2D STE parameters and circulating biomarkers will be collected.

Eligibility Criteria:
Inclusion Criteria:

* with malignant tumors
* will receive radiotherapy
* with cardiac exposure during the radiotherapy process
* could receive regular follow-up for 12 months
* written informed consent

Exclusion Criteria:

* satisfactory echocardiographic images could not be obtained
* moderate or severe valvular disease
* cardiomyopathy
* congenital heart disease
* refractory hypertension
* coronary artery disease\*
* heart failure
* arrhythmia requiring intervention
* pericarditis
* acute myocarditis
* participating in other clinical studies of drug intervention
* severe liver and kidney dysfunction
* autoimmune disease
* pulmonary hypertension

coronary artery disease: at least 50% stenosis besed on previous coronary angiography or CTA, or with a history of percutaneous coronary stent implantation.

\*: with LVEF\<50%, unstable angina，or acute myocardial infarction within 3 months.